- UCB’s 2025 revenue forecast is set between €6.5 billion to €6.7 billion, slightly below the estimated €6.82 billion.
- The company expects an adjusted EBITDA margin of 30%, compared to the forecast of 30.2%.
- Projected core EPS for 2025 ranges from €6.80 to €7.40, close to the estimated €7.17.
- For 2024, UCB’s core EPS was €4.98, up from €4.20, and above the estimated €4.49.
- Revenue for 2024 reached €6.15 billion, marking a 17% year-over-year increase and exceeding the estimate of €5.88 billion.
- Cimzia sales were €2.03 billion, a decrease of 2.6% year-over-year, slightly surpassing the estimate of €2.01 billion.
- Briviact sales came in at €686 million, outperforming the estimated €674.1 million.
- Evenity’s revenue grew by 72% year-over-year, totaling €103 million, slightly under the expected €106.5 million.
- Bimzelx saw a significant increase in sales, reaching €607 million, up from €148 million the previous year, surpassing the estimate of €551 million.
- The adjusted EBITDA for 2024 was €1.48 billion, up by 9.4% year-over-year, beating the anticipated €1.43 billion.
- Gross profit for 2024 was recorded at €4.40 million, above the estimate of €4.07 billion.
- Net income reached €1.07 billion, a substantial increase from €343 million year-over-year, and well above the estimated €596.3 million.
- Net debt decreased by 33% year-over-year to €1.45 billion.
- The annual dividend per share increased to €1.39 from €1.36 year-over-year, just shy of the estimated €1.40.
- Analysts’ ratings on UCB include 13 buys, 7 holds, and 2 sells.
A look at UCB SA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 2 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, UCB SA‘s long-term outlook seems promising with a strong focus on resilience and momentum. The company has received a high score in momentum, indicating positive market sentiment and potential for future growth. Additionally, UCB SA has demonstrated resilience with a commendable score in this aspect, suggesting a capacity to weather economic uncertainties.
While UCB SA may not be leading in terms of value, dividend, or growth scores, the overall outlook for the company remains optimistic. With its specialization in treating central nervous system disorders and inflammatory diseases on a global scale, UCB SA is positioned to capitalize on its strengths and navigate challenges effectively in the biopharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
